TABLE 2

Longitudinal Changes in the Markers of CVD-RFs

Baseline6 mo12 mo24 mo36 mo
n% (95% CI)n% (95% CI)n% (95% CI)n% (95% CI)n% (95% CI)
EBP23843.6 (36.3–51.3)20620.2 (14.7–27.1)21316.8 (11.9–23.2)19810.9 (7.0–16.5)19015.5 (10.6–22.0)
IFG23426.0 (19.9–33.1)1905.2 (2.7–9.7)2024.3 (2.2–8.3)1914.1 (2.0–8.2)1813.9 (1.8–8.1)
Diabetes23912.6 (8.2–18.7)2005.9 (3.2–10.9)2061.9 (0.7–5.3)1931.8 (0.6–5.2)1870.6 (0.1–3.8)
Dyslipidemia23875.2 (68.7–80.8)20453.1 (45.4–60.7)21026.8 (20.7–33.8)19625.8 (19.6–33.0)18429.4 (22.6–37.3)
LDL-C ≥130 mg/dL2387.9 (4.7–13.1)2046.9 (3.8–12.2)2105.3 (2.8–10.0)1975.0 (2.5–9.7)1864.2 (2.0–8.8)
HDL-C <40 mg/dL23863.5 (56.2–70.3)20442.4 (34.8–50.4)21018.7 (13.6–25.2)19714.1 (9.6–20.2)18615.2 (10.4–21.6)
Triglycerides ≥130 mg/dL23840.6 (33.5–48.2)20414.2 (9.7–20.3)2106.8 (4.0–11.3)19712.5 (8.3–18.4)18611.4 (7.3–17.4)
Abnormal triglyceride–to–HDL-C ratio22653.7 (45.9–61.3)19523.7 (17.5–31.1)2019.8 (6.2–15.2)18811.0 (7.1–16.9)17513.3 (8.7–19.8)
Elevated HOMA-IRa20975.8 (68.9–81.5)19126.2 (20.0–33.6)20621.1 (15.6–27.7)19118.5 (13.3–25.2)18525.0 (18.8–32.4)
Insulin >17.0 U/mL23073.8 (67.1–79.5)19629.9 (23.3–37.3)20616.9 (12.1–23.0)18914.9 (10.3–21.1)18520.6 (15.0–27.5)
HbA1c ≥6.5%2315.9 (2.9–11.8)1991.9 (0.6–5.8)2061.8 (0.6–5.6)1932.1 (0.7–6.1)1911.2 (0.3–4.7)
hs-CRP ≥0.3 mg/dL23875.1 (68.4–80.8)20342.6 (34.9–50.6)21029.5 (23.0–37.0)19523.6 (17.6–30.8)18725.1 (18.8–32.8)
  • Changes in the prevalence (CI) of multiple CVD-RF variables determined at baseline (preoperative) and the 6-, 12-, 24-, and 36-mo time points.